Barrett's esophagus secondary prevention

Jump to navigation Jump to search

Barrett's Esophagus Microchapters


Patient Information


Historical Perspective




Differentiating Barrett's Esophagus from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Endoscopic Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Barrett's esophagus secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Barrett's esophagus secondary prevention

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Barrett's esophagus secondary prevention

CDC on Barrett's esophagus secondary prevention

Barrett's esophagus secondary prevention in the news

Blogs on Barrett's esophagus secondary prevention

Directions to Hospitals TreatingBarrett's esophagus

Risk calculators and risk factors for Barrett's esophagus secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Hamid Qazi, MD, BSc [2], Amresh Kumar MD [3]


Effective measures for the secondary prevention of Barrett's esophagus include primary prevention along with endoscopic surveillance every 3-5 years for no dysplasia, 6-12 months for low-grade dysplasia, and every 3 months for high-grade dysplasia in the absence of eradication therapy.

Secondary prevention

Recommendations for secondary prevention of Barrett's esophagus include the primary prevention along with the following:

Weak recommendation, moderate-quality evidence: Endoscopic surveillance in patients with Barrett's esophagus The following intervals are recommended:

  1. Use proton pump inhibitors in doses greater than once daily. There is no evidence that higher doses produce a risk reduction in cancer.
  2. Titrate proton pump inhibitors dose by esophageal pH monitoring.
  3. Anti-reflux surgery. This is not more effective than medical therpay.

Risks and benefits of long-term PPI therapy should be discussed with the patients.


  1. 1.0 1.1 1.2 Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). "American Gastroenterological Association medical position statement on the management of Barrett's esophagus". Gastroenterology. 140 (3): 1084–91. Unknown parameter |month= ignored (help)

Template:WH Template:WS